GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older

Phase 3

Completed

Conditions: Influenza

Interventions: Biological: Influsplit™ Tetra (Fluarix™ Tetra)
Biological: Pneumovax™ 23
Biological: Placebo (Saline)

First Posted Date: 2014-08-18

Last Posted Date: 2018-04-03

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 357

Registration Number: NCT02218697

Locations: 🇫🇷
GSK Investigational Site, Tours, France

Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: GSK2636771
Drug: Enzalutamide

First Posted Date: 2014-08-13

Last Posted Date: 2020-10-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 37

Registration Number: NCT02215096

Locations: 🇬🇧
GSK Investigational Site, Sutton, United Kingdom

Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria

Phase 3

Completed

Conditions: Malaria, Vivax

Interventions: Drug: Tafenoquine Placebo
Drug: Tafenoquine
Drug: Chloroquine
Drug: Primaquine Placebo
Drug: Primaquine

First Posted Date: 2014-08-13

Last Posted Date: 2018-05-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 251

Registration Number: NCT02216123

Locations: 🇻🇳
GSK Investigational Site, Ho Chi Minh, Vietnam

A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban

Phase 1

Terminated

Conditions: Embryo Transfer

Interventions: Drug: Epelsiban
Drug: Placebo
Drug: Ortho-Cylcen (21)® tablet
Drug: Oxytocin

First Posted Date: 2014-08-11

Last Posted Date: 2017-05-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 33

Registration Number: NCT02213029

Locations: 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States

Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents

Phase 2

Completed

Conditions: Infections, Meningococcal

Interventions: Biological: Bexsero
Other: Saline Placebo
Biological: Havrix
Biological: MenABCWY

First Posted Date: 2014-08-08

Last Posted Date: 2019-06-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1063

Registration Number: NCT02212457

Locations: 🇵🇱
GSK Investigational Site, Wroclaw, Poland

A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis

Phase 2

Completed

Conditions: Gastroparesis

Interventions: Drug: Placebo
Drug: Camicinal

First Posted Date: 2014-08-06

Last Posted Date: 2017-12-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 114

Registration Number: NCT02210000

Locations: 🇺🇸
GSK Investigational Site, Norfolk, Virginia, United States

To Evaluate the Efficacy and Tolerability of Sodium Bicarbonate Toothpaste

Phase 2

Completed

Conditions: Oral Hygiene

Interventions: Drug: Sodium bicarbonate plus sodium fluoride
Drug: Sodium fluoride

First Posted Date: 2014-08-04

Last Posted Date: 2017-04-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 247

Registration Number: NCT02207907

Locations: 🇺🇸
GSK Investigational Site, Las Vegas, Nevada, United States

A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Umeclidinium
Drug: Tiotropium
Drug: Tiotropium matching placebo
Drug: Umeclidinium matching placebo

First Posted Date: 2014-08-04

Last Posted Date: 2018-01-24

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1017

Registration Number: NCT02207829

Locations: 🇺🇦
GSK Investigational Site, Zaporizhzhia, Ukraine

To Evaluate Efficacy and Tolerability of Sodium Bicarbonate Toothpaste and Its Effect on Opportunistic or Resistant Organisms

Phase 2

Completed

Conditions: Oral Hygiene

Interventions: Drug: Sodium bicarbonate and sodium fluoride
Drug: Sodium fluoride

First Posted Date: 2014-08-04

Last Posted Date: 2018-07-31

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 246

Registration Number: NCT02207400

Locations: 🇺🇸
GSK Investigational Site, Fort Wayne, Indiana, United States

Helium-3 MRI Imaging Study in COPD

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Device: He-3 MRI
Drug: Salbutamol
Drug: Ipratropium
Device: MRI

First Posted Date: 2014-08-04

Last Posted Date: 2017-06-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 11

Registration Number: NCT02207452

Locations: 🇬🇧
GSK Investigational Site, Sheffield, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy